Review article: Toxic effects of aluminum on bone formation

Journal of Hard Tissue Biology

Volumn 12, Issue 2, 2003, Pages 44-48

  Daiman, Tateo ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Aluminum; animal models; bone toxicity; osteodystrophy

Indexed keywords

EID: 77952889677     PISSN: 13417649     EISSN: None     Source Type: Journal    
DOI: 10.2485/jhtb.12.44     Document Type: Article

References (56)

1. Goyer R.A. and Clarkson T.W.: Toxic effects of metals. In: Casarett and Doulh Toxicology. The basic science of poisons, ed. by Klaassen CD., McGraw-Hill., New York, 2001, pp 811-867
2. Cotton F.A. and Wilkinson G.: Advanced Inorganic Chemistry. a Comprehensive Text. John Wiley and Sons. New York. 1980
3. Platts M.M. Goode G.C. and Hislop J.S.: Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J. 2: 657-660. 1977
4. Piérides A.M. Edwards W.G. Jr., Cullu U.S. Jr. McCall J.T. and Ellis H.A.; Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int. 18: 115-124. 1980
5. Parkinson I.S. Feest T.G. Ward, M.K. Fawcett R.W.P. and Kerr D.N.S.: Fracturing dialysis osteodystrophy and dialysis encephalopathy. an epidemiological survey. Lancet. 1: 406-409, 1979
6. Parsons V. Davies C., Goode C. Ogg C. Siddiqui J.: Aluminum in bone from patients with renal failure. Br Med J, IV: 273-275. 1971
7. Goodman W.G. and Duarte M.E.L.: Aluminum: Effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metab. 17: 221-232. 1991
8. Buchanan M.R., Ihle B.U. and Dunn C.M.: Haemodialysis related osteomalacia; a staining method to demonstrate aluminium. J Clin Pathol. 34: 1352-1354, 1981
9. Huffer W.E., Zhu J.M. Ruegg P.: Modified acidic solochrome aurine stain for video image analysis of aluminum lines in bone biopsies. J Histotechnol 19: 115-119. 1996
10. Kraurt J.A. Shinaberger J.H., Singerb F.R., Sherrard D.J. Saxton J., Miller J.H. Kurokawa K., Cobum J.W.: Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. Kidney Int. 23: 725-730, 1983
11. Morrissey J.J., Rothstein M. Mayor G., Slatopolsky E.: Suppression of parathyroid hormone secretion by aluminum. Kidney Int. 23: 699-704. 1983
12. Wilhelm M. Zhang X.-J. Hafner D. and Ohnesorge F.K.: Single-dose toxicokinetics of aluminum in the rat. Arch Toxicol 66: 700-705. 1992
13. World Health Organization (WHO)Toxicological evaluation of certain food additives and contaminates. WHO food additives series 24. Cambridge University Press. Cambridge. 1989
14. Gupta S.K. Waters D.H. and Gwilt P.R.: Absorption and disposition of aluminum in the rat. J Pharmacol Sci. 75: 586-589. 1986
15. Yokel R.A. and McNamara P.J.: Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. Toxicol Appi Pharmacol. 95: 32-43. 1988
16. Ellis H.A., McCarthy J.H. and Herrington J.: Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride; relationship to impaired bone mineralisation. J Clin Pathol. 32: 834-832, 1979
17. Robertson J.A. Felsenfeld A.J. Haygood C.C., Wilson P. Clarke C. and Liach F.: Animal model of aluminum-induced osteomalacia: Role of chronic renal failure. Kidney Int. 23: 327-335. 1983
18. Teraki Y. Uchiumi A., and Takatsu A.: Staining for histologic diagnosis of aluminum osteopathy-Application of confocal laser scanning microscopy to observation for aluminum in bones from aluminum-treated, subtotally nephreetomized rats. Acta Anat Nippon. 73: 317-328. 1998
19. Talwar H.S. Hari Reddi A. Menczel J., Thomas W.C. Jr. and Meyer J.L.: Influence of aluminum on mineralization during matrix-induced bone development. Kidney hit, 29: 1038-1042. 1986
20. Ikeda K., Matsumoto T. Morita K., Kurokawa K. and Ogata E.: Inhibition of in vitro mineralization by aluminum in a clonal osteoblast-like cell line, MC3T3-E1. Calcif Tissue Int. 39: 319-323. 1986
21. Blumenthal N.C. and Posner A.S.: In vitro model of aluminum-induced osteomalacia; inhibition of hydroxyapatite formation and growth. Calcif Tissue Int. 36: 439-441. 1984
22. Cannata Andia J. B.: Aluminium toxicity: its relationship with bone and iron metabolism. Nephrol Dial Transplant. 11: 69-73. 1996
23. Andress D.L. Maloney N.A. Endres D.B. Sherrard D.J.: Aluminum-associated bone disease in chronic renal failure: High prevalence in a long-term dialysis population. J Bone Miner Res. 1: 391-398, 1987
24. Cann C.E., Prussin S.G., Cordan G.S.: Aluminum uptake by the parathyroid glands. J Clin Endocrin Metab. 49: 543-545. 1979
25. Virgos M.J. Diaz Lopez. I.B. Menendez Frage P. Gomez Alonso C., Cannata J.B.: Parathyroid and serum calcium response in acute aluminium exposure in renal failure. Trace Eleni Med. 11: 68-72, 1994
26. Cannata J.B. Briggs.I.D. Junor B.J.R. Gordons S.F. Beastall G.: Effect of acute aluminium overload on calcium and parathyroid hormone metabolism. Lancet, 1983:1: 501-503. 1983
27. Chan J.C.M. Kodroff M.B. Landwehr D.M.: Effects of 1,25-dihydroxyvilamin D, on renal function, mineral metabolism and growth in children with severe chronic renal failure. Pediatrics. 68: 559-571. 1981
28. Chan Y-L. Alfrey A.C. Posen S. Lissner D. Hills E. Dunstan C.R., and Evans. R.A.: Effect aluminum on normal and uremic rats: Tissue distribution, vitamin D metabolites, and quantitative bone histology. Calcif Tissue Int. 35: 344-351. 1983
29. Chan J.C.M. Jacob M. Brown S. Savory J. Wills M.R.: Aluminum metabolism in rats: Effects of vitamin D. dihydrotach-ysterol. 1. 25-dihydroxyvitamin D and phosphate binders. Nephron. 48: 61-64. 1988
30. Cannata J.B. Sauarez C. Cuesta M.V. et al.: Gastrointestinal aluminium absorption: is it modulated by the iron-absorptive mechanism? Proc Eur Dial Transplant Assoc. 21: 354-359. 1984
31. Cannata J.B. Fernandez Soto I. Fernandez Menendez M.j. Fernandez Martin J.L. McGregor S. Brock J.H. Halls D.: Role of iron metabolism in absorption and cellular uptake of aluminium. Kidney Int. 39: 799-803. 1991
32. Fernandez Menendez M.J. Fell G.S. Brock J.H. Cannata J.B.: Aluminium uptake by intestinal cells: effect of iron status and precomplexation. Nehrol Dial Transplant. 6: 672-674. 1991
33. Trapp G.A.: Plasma aluminium is bound to transferrin. Life Sci. 33: 311-316. 1983.
34. Kasai K. Hori M.T. Goodman W.G.: Transferrin enhances the antiproliferative effect of aluminum in osteoblast-like cells. Am J Physiol. 260: E537-E543. 1991
35. Ott S.M. Maloney N.A. Klein G.L. Alfrey A.C. Anient M.E. Coburn J.W.: Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med. 98: 910-914. 1983.
36. Quarles L.D. Gitelman H.J. Drezner M.K.: Induction of de novo bone formation in the beagle. A novel effect of aluminum. J Clin Invest. 81: 1056-1066. 1988
37. Sedman A.B. Alfrey A.C. Miller N.L. Goodman W.G.: Tissue and cellular basis for impaired bone formation in aluminum-related osteomalacia in the pig. J Clin Invest, 79: 86-92. 1987
38. Blair U.C. Finch J.L. Avioli R. Crouch E.C. Slatopolsky E., Teitelbaum S.L.: Micromolar aluminum levels reduce 3H-tymidine incorporation by cell line UMR-106. Kidney Int. 35: 1119-1125. 1989
39. Eichom G.L. Butzow J.J. Clark P. Von Hahn H.P. Rao G. Heim J.M. Tarieu E.: Metal ion-nucleic acid interactions. Aging and Alzheimer s disease. In: Inorganic Chemistry in Biology and Medicine, ed. by Martell M.E. American Chemical Society, New York. 1980. pp 75-87
40. Martin R.B.: The chemistry of aluminum as related to biology and medicine. Clin Chem. 32: 1797-1806. 1986
41. Siegal N., Coughlin R., Haug A.: A thermodynamic and electron paramagnetic resonance study of structural changes in calmodulin induced by aluminum binding. Biochem Biophys Res Commun. 115: 512-517. 1983
42. Lieberherr M. Grosse B. Coumot-Winner G. Hermann-Erlee M.P. Balsan S.: Aluminum action on mouse bone cell metabolism and response to PTH and 1.25(OH)2D3. Kidney Int. 31: 736-743. 1987
43. Yokel R.A.: Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Biol Trace Eleni Res, 53: 193-203. 1996
44. Kurokawa K. Marumo F. Ogura Y. Ono T. and Suzuki M.: Aluminum-associated bone disease: consideration on the pathogenesis and the effects of deferoxamine treatment. In: Toxicology of metals: Clinical and experimental research, ed by Brown S.S. and Kodama Y. Halsted Press. New York. 1987. pp 211-217
45. Marumo F. Umetani N. Sato N. Takahashi Y.: Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease. In: Toxicology of metals: Clinical and experimental research. ed by Brown S.S. and Kodama Y. Halsted Press. New York. 1987. pp 219-231
46. Domingo J.L.: Adverse effects of aluminium-chelating compounds for clinical use. Adverse Drug React Toxicol Rev. 15: 145-165. 1996
47. Domingo J.L. Llobet J.M. Gomez M. and Corbella J.: Acute aluminum intoxication: a study of the efficacy of several antidotal treatments in mice. Res Commun Chem Pathol Pharmacol. 53: 93-104. 1986
48. Domingo J.L. Gomez M. Llobet J.M. and Corbella J.: Comparative effects of several chelating agents on the toxicity. distribution and excretion of aluminium. Hum Toxicol. 7: 259-262. 1988
49. Domingo J.L. Gomez M. Llobet J.M. and Corbella J.: Citric, malic, and succinic acids as possible alternatives to aluminium toxicity. Clin Toxicol. 26: 67-69. 1988
50. Yokel R.A., Dana A.K. Jackson E.G.: Evaluation of potential aluminium chelators in vitro by aluminum solubilization ability, aluminium mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminium. J Pharmacol Exp Therap. 257: 100-106. 1991
51. Graff L., Muller G. Burnel D.: In vitro and in vivo comparartive studies of chelation of aluminum by some polyaminocarboxylic acid. Res Commun Chem Pathol Pharmacol 88: 271-292. 1995
52. Gomez M. Esparza J.L. Domingo J.L. Corbella J. Singh P.K. and Jones M.M.: Aluminium distribution and excretion: A comparative study of a number of chelating agents in rats. Pharmacol & Toxicol. 82: 295-300. 1988
53. Orlon R.B. De Veber L.L. and Sulh H.M.B.: Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can. J Ophthalmol. 20: 153-156. 1985
54. Davies, S.C. Marcus R.E. Hungerford J.L. Miller M.H. Arden G.B. and Huehns E.R.: Ocular toxicity of high-dose intravenous desferoxamine. Lancet II: 181-184. 1983
55. Ebina Y. Okada S. Ilamazaki S. Ogino F.L.I.J.L. Midorikawa O.: Nephrotoxicity and renal cell carcinoma after use of iron-and aluminiim-nitrilotriacetate complexes in rats. J Natl Cancer Int. 76: 107-113. 1986
56. Ebina Y. Okada S. Hamazaki S. Toda Y. and Midorikawa O.: Impairment of bone formation with aluminum and ferric nitrilotriacetate complexes. Calcif Tissue Int. 48: 28-36. 1991